

**From:** Ryan Lane <pharma@smiconferences.co.uk>  
**To:** Kester, Tonykester@aging.sc.gov  
**Date:** 7/5/2016 9:26:56 AM  
**Subject:** Superbugs USA: Pfizer join the exceptional speaker line-up alongside BARDA, Janssen, NIH and more

---

**NEW SPEAKER:** Pfizer's Vice President and CSO - Bacterial Vaccines, has just been added onto the notable speaker line-up.

## Superbugs & Superdrugs USA

The Global Attack Against Bacteria's Defensive Walls  
Conference: Nov 14th & 15th 2016 | Interactive Workshop: Nov 16th 2016  
Renaissance Woodbridge Hotel, Iselin, New Jersey, USA

**\*\* \$400 EARLY BIRD SAVING ENDS JULY 15TH \*\***

Register online at: [www.superbugs-usa.com](http://www.superbugs-usa.com)

### Sponsorship Opportunities:

To sponsor the conference and have your logo featured on the brochure before it prints next week, contact Alia Malick on  
Tel: +44 (0)20 7827 6168

Dear Mr Tony Kester,

Bringing in voices from some of the most senior industry thought leaders in infectious disease and drug discovery such as **BARDA, Pfizer, Janssen** and the **UNT Health Science Centre**, SMI's next **conference** in their portfolio of Superbugs events arrives in New Jersey this autumn to discuss new clinical advancements and funding opportunities to tackle the growing global threat of anti-microbial resistance (AMR).

If you haven't seen a flyer yet for **Superbugs & Superdrugs USA**, [click here](#) for further details or scroll down for **agenda highlights**.

The program will hone in on key topics such as public private partnerships, collaboration, R&D, scientific priorities for antibiotic discovery, novel antibacterial therapeutic approaches, antibiotic stewardship, rapid diagnostic tools, combination therapies, resistance prevention, plus much more!

[Download Flyer](#) or  
[contact us](#) to request a brochure

### GET INVOLVED!

**\$400 Early bird ends July 15th!**

Register online at

[www.superbugs-usa.com](http://www.superbugs-usa.com)

or contact Matthew Apps on:

Tel +44 (0)20 7827 6093

Email: [mapps@smi-online.co.uk](mailto:mapps@smi-online.co.uk)

---

### FEATURED SPEAKERS INCLUDE:

- Dr Christopher Houchens, Branch Chief, Antibacterial's Program, **BARDA**
- Dr Rosemarie Aurigemma, Chief, Biodefense Drug Development Section, **NIH**
- Dr Anthony Simon Lynch, Senior Scientific Director, **Janssen Research & Development LLC**
- Dr Annaliesa Anderson, Vice President and CSO Bacterial Vaccines, **Pfizer**
- Dr Alita Miller, Director of Biology, **Entasis Therapeutics**
- William J Weiss, Director, Pre-Clinical Services, **UNT Health Science Center**

- Dr Domingo Gargallo-Viola, Co-Founder and CSO, **ABAC Therapeutics**
- Dr David Cook, Chief Scientific Officer, **Blueberry Therapeutics Ltd**

We hope you are able to join us for what promises to be an insightful and engaging conference.

Kind Regards,

The Superbugs & Superdrugs USA Team 2016

---

**PRELIMINARY PROGRAM:** *More details coming soon!*

The brochure will be released next week! In the meantime, take a sneak peek into how the agenda is shaping up! Stay posted on event updates at [www.superbugs-usa.com](http://www.superbugs-usa.com)

Day One: 14th Nov 2016	Day Two: 15th Nov 2016
<p>8.00 <b>Registration &amp; Coffee</b></p> <p>8.30 Chairman's Opening Remarks</p> <p>8.40 A global plan to prevent, detect, and respond to the next killer disease</p> <p>9.20 NIAID and National Strategy for CARB</p> <p>10.00 <b>Morning Coffee</b></p> <p>10.30 BARDA's end-to-end support of antibacterial product development</p> <p>11.10 CDER's new molecular entities and new therapeutic biological products</p> <p>11.50 Global action plan on antimicrobial resistance</p> <p>12.30 <b>Networking Lunch</b></p> <p>1.30 Enabling drug discovery and development to address the crisis of antimicrobial resistance</p> <p>2.10 Novel protein-based biologics for the treatment and prevention of serious bacterial infections</p> <p>2.50 Fighting multi-resistant gram-negative infections</p> <p>3.30 <b>Afternoon Tea</b></p> <p>4.00 Targeting mechanisms of resistance using protein resistance neutralizers</p> <p>4.40 A novel bispecific antibody for treating pseudomonas aeruginosa Infections</p> <p>5.20 <b>PANEL DISCUSSION:</b> The politics of antibiotic resistance factor MCR</p> <p>6.00 Chairman's Closing Remarks and Close of Day One</p>	<p>8.00 <b>Registration &amp; Coffee</b></p> <p>8.30 Chairman's Opening Remarks</p> <p>8.40 Generation and tailoring chemical matter for antibacterial discovery</p> <p>9.20 Novel monoclonal antibodies for the prevention and treatment of bacterial infections</p> <p>10.00 <b>Morning Coffee</b></p> <p>10.30 Antimicrobial combination therapy: Use and disuse</p> <p>11.10 What can be done in order to be successful?</p> <p>11.50 Addressing the evolving challenge of <math>\beta</math>-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broad spectrum activity against Class A, C and D enzymes</p> <p>12.30 <b>Networking Lunch</b></p> <p>1.30 Mastering antimicrobial stewardship with the help of molecular diagnostics</p> <p>2.10 Rapid diagnostic tools</p> <p>2.50 <b>Afternoon Tea</b></p> <p>3.20 New treatment for prevention of infections</p> <p>4.00 Thousands of new antibiotic classes: The road to patients</p> <p>4.40 Chairman's Closing Remarks and Close of Day Two</p>
	<p><b>PLUS:</b> Don't forget our <a href="#">interactive workshop</a> on "The Use of Animal Models in PreClinical Drug Development" taking place on <b>16th November 2016</b></p>

Register online at: [www.superbugs-usa.com](http://www.superbugs-usa.com)

You are registered as: kester@aging.sc.gov Your Unique Reference Number: 92804565  
 To update your contact preferences please go to <http://www.smi-online.co.uk/update-preferences>